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Cardiac biomarkers in acute coronary 
syndromes
INTRODUCTION                                                                
Ischemic heart disease is the number one cause of mortality and 
morbidity in the Western world, and this unfortunate reality is unlikely 
to change in the future.  In fact, it is believed that in 2020 acute coronary 
syndromes (ACS) will over-run infectious disease and cancer to become 
the leading cause of death and disability, not only in industrialized 
countries, but also in the developing world.(1) However, despite these 
facts the diagnostic approach to ACS remains one of our most diffi cult 
and controversial challenges.(2)
As our understanding of the pathobiology of atherothrombosis has 
improved, researchers have attempted to evaluate the activities of 
these biological processes by measuring markers in plasma or urine 
(i.e. biomarkers). Indeed, several conventional and promising new 
markers of myocardial injury have been identifi ed.  
This overview focuses on established and emerging biomarkers and 
their role in the diagnosis, risk stratifi cation, and prognostication of 
patients presenting with ACS.
HISTORICAL BACKGROUND TO THE DIAGNOSIS 
OF ACUTE CORONARY SYNDROMES 
In 1971, the World Health Organization (WHO) developed a defi nition 
of acute myocardial infarction (AMI), which requires the presence of 
2 of the following 3 major criteria: chest pain suggestive of myocardial 
ischemia, electrocardiographic (ECG) manifestations and indicative 
laboratory changes.(3) This was a major innovation, and by the early 
1990s the WHO defi nition had become a cornerstone in clinical and 
laboratory medicine.  
Despite increasing focus on biochemical markers during the last 
2 decades, the search for the optimal marker is ongoing. Early markers 
of AMI such as aspartate aminotransferase, lactate dehydrogenase and 
creatine kinase (CK), were non-specifi c and did not provide defi nitive 
proof of myocardial involvement. Assays to measure the enzymatic 
activity of the creatine kinase muscle brain isoenzyme (CK-MB) was an 
important advancement, especially in terms of improved specifi city.(4) 
Although CK-MB is not ideal for early risk stratifi cation, it became the 
standard against which new biochemical markers are compared with 
respect to diagnostic accuracy and quantifi cation of myocardial necrosis. 
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  Cardiac biomarkers play a signifi cant 
role in the diagnosis, risk assessment, and management of 
patients with acute coronary syndromes [ACS].  Several 
biomarkers identify different components of the 
pathophysiology of ACS: troponins are markers of myocyte 
necrosis, natriuretic peptides refl ect neurohormonal 
activation and myocardial dysfunction, and C-reactive 
protein refl ects various infl ammatory processes.  Whilst 
there are a number of established and novel biomarkers to 
assess ischemia, necrosis and myocardial dysfunction in 
coronary artery disease, it is probable that no single 
biomarker will emerge that provides appropriate 
information for all clinical settings of ACS.  This suggests 
that ongoing efforts in plasma-based biomarker research 
should concentrate on the use of a multimarker approach 
to enhance our diagnosis, prognostic assessment, and 
management of patients with suspected ACS, as compared 
with using individual markers alone.
It is recommended that current practice involve the 
selective use of biomarkers in patients in whom a more 
complete assessment of risk is desired.  At present, routine 
biomarker measurement is not advocated until further 
data become available, which will support the benefi t of 
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By the mid-1990s, cardiospecifi c troponins were identifi ed as effective 
markers of myocardial injury.  On the basis of their improved sensitivity 
and greater tissue-specifi city, troponins have evolved into our most 
important diagnostic markers, becoming the biochemical “gold 
standard” for the diagnosis of myocardial injury in patients with acute 
chest pain.  This led to the realization that the defi nition of AMI needed 
to be revisited.
In 2000, a joint European Society of Cardiology and American College 
of Cardiology Committee updated the defi nition of AMI, identifying 
troponins as the cardiac markers of choice.(5) More recently, this 
committee has proposed the following defi nition of AMI: 
 Typical rise and / or gradual fall of troponin (and measurements of 
CK-MB only to be performed if troponin assays are not available), 
with at least one of the following:
a.  Ischemic symptoms
b.  Development of pathologic Q waves on the ECG 
c.  ECG changes indicative of ischemia (ST-segment elevation or 
depression)
d.  Coronary artery intervention (e.g. angioplasty)
Pathologic fi ndings of an AMI
CRITERIA FOR BIOMARKER EVALUATION IN ACS
Morrow and De Lemos have proposed that evaluation of the clinical 
utility of new biomarkers requires at least 3 fundamental questions to 
be answered.(6)  
1. Can the clinician measure the biomarker? 
The biomarker must be easy to measure in a cost-effective manner, and 
not require specialized plasma collection techniques or assay techniques. 
Available assays should be easily accessible and have a prompt 
turnaround time.
2.  Does the biomarker add new information to the risk 
assessment?    
It is important that the proposed biomarker provide information, 
which adds to or improves upon existing available tests. A strong 
and consistent association should exist between the biomarker and 
patients with ACS with respect to clinical outcome to allow for 
prognostic application of that marker. 
3. Will the biomarker help the clinician to manage patients?
As outlined in Figure 1, each biomarker has the potential to address 
different mechanisms in the pathobiology of plaque instability and, 
■
■
therefore, may be of use for the early detection of sub-clinical disease, 
diagnosis of ACS, risk stratifi cation, selection of appropriate therapy, and 
monitoring of disease progression. Each of these potential uses merits 
consideration in the evaluation of a biomarker’s ability to enhance the 
management of patients presenting with ACS. 
Several biomarkers meet these criteria, but only few are ready for 
clinical practice.    
TROPONINS                                                                        
Cardiac Troponin T and I are cardiac regulatory proteins that control 
the calcium-mediated interaction of actin and myosin.(7) Both have 
cytosolic and structural pools, with most existing in the structural 
pool.(8) An important advantage of the troponins is that their isoforms 
are unique to cardiac myocytes, with most of the early troponin release 
during an AMI coming from the cytosolic pool. Subsequent release is 
prolonged, with degradation of the actin and myosin fi laments in the 
area of damage. 
The diagnostic cut-off for cardiac troponins remains a source of 
contention. The ESC / ACC consensus document recommended that 
each laboratory should defi ne its cut-offs for each test at the 99th 
percentile of a normal reference population, and that this cut-off value 
should be measurable with a coeffi cient of variation (CV) of 10 percent 
or less.(5) However, current assays are unable to detect tropinin in the 
majority of normal healthy individuals and are imprecise at this low 
level.  Until better assays are available, some have suggested that the 
Adapted from Circulation 2007; 115:949-952
hsCRP = High sensitivity C-Reactive Protein  
B-Type NP = B-Type Natriuretic Peptides (BNP / NT-proBNP)
IMA = Ischemia-Modifi ed Albumin 
CK-MB = Creatine Kinase Muscle Brain Isoenzyme 
H-FABP = Heart-type Fatty Acid Binding Protein 
PAPP-A = Pregnancy-Associated Plasma Protein - A



































level defi ned as abnormal be raised to that value at which a specifi c 
assay has a CV of 10 percent of less.(9) Currently, it is recommended 
that the cut-off (clinical discriminator) value of Troponin T or I used for 
the defi nition of AMI is 0.1 ng/mL according to ROC analysis.    
1.  Use for diagnosis of AMI 
Cardiac troponin concentrations usually begin to rise 2 to 3 hours after 
the onset of AMI (Figure 2), with up to 80% of patients having elevated 
levels within this time frame.(10) Troponin data is, therefore, additive to 
ECG data and superior to CK-MB results. Patients with ST-elevation 
myocardial infarction (STEMI) are different from those with unstable 
angina (UA) and non ST-elevation myocardial infarction (NSTEMI) 
in that they do not need biomarker measurements before institution 
of reperfusion therapy. However, STEMI patients presenting with 
elevated troponin on arrival have a lower rate of coronary recanalization, 
both with thrombolysis and direct percutaneous coronary intervention 
(PCI) and have adverse short and long-term prognosis.(11) In patients 
without diagnostic ST-segment elevation, serial troponin testing  should 
be performed after 6 hours if the initial values are indeterminate to 
diagnose or exclude AMI with high accuracy.
Elevations in cardiac troponins after AMI persist for up to 10 days, 
permitting late diagnosis.(12) In contrast, CK-MB elevations return to 
baseline levels by 36 to 48 hours and cannot be used for late diagnosis. 
Previously, new elevations in CK-MB were used to detect reinfarction. 
Troponins can now be used for this purpose, bearing in mind that a 
20% increase from prior levels is supportive for the detection of 
ongoing ischemia (Figure 3).  
It is important to note that, while troponin measurement is a useful tool 
for the diagnosis of ACS, several limitations exist. Since troponin 
concentrations only begin to rise 2 to 3 hours after the onset of AMI, 
patients who present earlier will have negative troponin levels, thereby 
limiting the diagnostic capabilities of this biomarker. Certain patients 
with unstable angina present with acute chest pain and myocardial 
ischemia, and yet have negative troponin levels. It has been shown that 
these patients still have a high incidence (6-8%) of AMI at 30 days, even 
with the use of state of-the-art evidence-based therapy.(13) Similarly, a 
subset of patients with ACS may not develop necrosis despite severe 
coronary artery disease and myocardial ischemia. They clearly need 
further characterization and advice but escape scrutiny due to negative 
troponin results. Owing to their tissue specifi city, another limitation of 
troponins is their inability to discriminate between ischemic and non-
ischemic myocardial injury, such as traumatic injury, congestive heart 
failure, pericarditis, and myocarditis.(14)
2.  Prognostic Value
Troponin elevation has been shown to correlate with the severity of 
coronary disease and long-term mortality in patients presenting with 
STEMI and NSTEMI. A pooled analysis of 21 studies involving 18 982 
patients with ACS found that elevated troponins were also associated 
with an increased risk of cardiac death or reinfarction at 30 days (odds 
Figure is based on the Universal Defi nition of Myocardial Infarction Eur Heart J 2007; 
28:2525-2538.
FIGURE 2:  Time Course of Troponin and CK-MB in Blood after Onset of 
Myocardial Infarction
































 Adapted from UpToDate 2008
*  Troponin elevations persist for at least fi ve days and up to fourteen days after an AMI. 
Thus, if the Tn is normal and then becomes elevated, a new event rather than reinfarction 
has occurred.
FIGURE 3:  Algorithm for diagnosis of suspected early recurrent MI 
(reinfarction) after STEMI based upon clinical setting and troponins (tn)*
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ratio 3.44, 95% CI 2.94 - 4.03).(15) High-risk ACS patients with elevated 
troponin do better with early invasive therapy, glycoprotein 11b/111a 
inhibitors, anti-platelet agents and low molecular-weight heparins.(9) 
Thus, the impact of a positive or negative troponin at presentation 
would seem to be central to the management decision.  The degree 
of elevation of troponin also has signifi cant prognostic value, with 
the risk of death increasing proportionately with the absolute 
troponin level.(16)   
CK- MB ISOENZYME                                                           
Since CK is widely distributed in tissues, elevations in total serum CK 
lack specifi city for cardiac damage, and a consensus statement of the 
European Society of Cardiology and the America College of Cardiology 
concluded that total CK no longer has a role in diagnosing an AMI.(5) It 
has been recommended that the biochemical diagnosis of AMI be 
based upon the rise and/or fall in CK-MB when troponin assays are not 
available.  CK-MB typically begins to rise 4 to 6 hours after the onset of 
infarction and returns to baseline within 36 to 48 hours (Figure 2). 
Most assays for CK-MB measure CK-MB mass; such assays are more 
sensitive than active assays.  Because CK-MB comprises a lower fraction 
in skeletal muscle than in the heart, percentage criteria (from 2.5 to 
5 percent) have been proposed to distinguish skeletal muscle damage 
from cardiac damage.  These criteria are not recommended, since they 
improve specifi city, but do so at the cost of sensitivity in patients who 
have both skeletal and cardiac injury.(7)
Typical criteria for the diagnosis of an AMI require a total CK elevation 
twofold above normal with a simultaneously elevated CK-MB.  However, 
ischemic injury may occur in the presence of a normal total CK but 
elevated CK-MB.  In a review of almost 26 000 patients with NSTEMI , 
the primary endpoint of death or AMI at 180 days was signifi cantly 
higher in patients with elevated CK-MB, independent of whether total 
CK was normal or elevated.(17)
MYOGLOBIN                                                                        
The ubiquitous heme protein myoglobin is elevated in roughly similar 
proportions as CK-MB and troponins among patients with AMI.(18) 
However, several limitations exist to the use of serum myoglobin for 
the diagnosis of AMI:
 The rapid release and metabolism of myoglobin can result in an 
undulating pattern characterized by increases and decreases in 
serum myoglobin concentration that can lead to clinical 
confusion.(19) 
■
 Myoglobin also lacks specifi city for the heart and serum 
concentrations are elevated after injury to a variety of tissues, 
particularly skeletal muscle.  Myoglobin levels are also increased 
following recent cocaine use and in patients with impaired renal 
function due to decreased clearance.(20) 
Because of these limitations and absence of any advantage over 
troponins, myoglobin should not be routinely measured in patients with 
suspected AMI.
HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP) 
The acute phase reactant CRP is perhaps the best characterized of the 
currently available infl ammatory biomarkers. Clinically, CRP can be 
measured with several standardized, validated, and inexpensive high-
sensitivity assays.(21) Several prospective, epidemiological studies have 
demonstrated that hsCRP is an independent predictor of risk of AMI, 
stroke, peripheral arterial disease, and sudden death, even in apparently 
healthy individuals.(22) Levels of hsCRP of <1mg/ml, 1 to 3mg/ml, and 
>3mg/ml should be interpreted as lower, moderate and higher vascular 
risk, respectively.  Any clinical use of hsCRP is best limited to those at 
intermediate risk, that is individuals with anticipated 10-year event rates 
between 6% and 20%.
There is no evidence yet that lowering hsCRP will necessarily lower 
vascular risk.  Furthermore, there are still ongoing debates about the 
stability of CRP in stored (frozen) samples of plasma or serum, as well 
as about its biological intra-individual variability.(23) One ongoing, 
prospective, randomized study being conducted in apparently healthy 
individuals (the Use of Statins in Primary Prevention: An Intervention 
Trial Evaluating Rosuvastatin (JUPITER) study) is evaluating whether 
hsCRP-guided statin administration will have a favorable impact on 
cardiovascular disease. Thus, hsCRP may yet be proved to be a 
biomarker able to guide primary prevention studies.
B-TYPE NATRIURETIC PEPTIDES                                   
Brain natriuretic peptide (BNP) and its N-terminal amino acid fragment 
(NT-proBNP) are neurohormones synthesized predominantly in the 
ventricles and released into the circulation in response to ventricular 
dilation and pressure overload.  These peptides have been found to be 
useful in assisting with the diagnosis of congestive heart failure in 
dyspneic patients, with increasing levels correlating grossly with the 
severity of left ventricular dysfunction (LVD), both clinically and 
haemodynamically.(24) More recently, multiple large studies have shown 
BNP and NT-proBNP levels to be strong independent  predictors of 





also been demonstrated that NT-proBNP is able to defi ne not only 
myocardial necrosis, but also reversible ischemic changes in patients 
with ACS.(26) 
The mechanisms for the increase in NT-proBNP in patients with ACS 
and normal ejection fraction have not been precisely defi ned.  It has 
been suggested that cardiac myocytes secrete natriuretic peptides 
during the prolonged ischemic phase that precedes cell death.(26) 
Therefore, ischemia may be an additional stimulus for NT-proBNP 
synthesis.(27)
Furthermore, serial measurements of NT-proBNP may permit an on-
going assessment of risk in patients with ACS. Since this peptide is 
highest during the acute phase of presentation and then gradually falls 
over 6 months, elevated levels at any time period are associated with 
increased risk.(28)  This biomarker rises rapidly during the fi rst 24 hours 
following an AMI and may be considered as an additional marker in the 
diagnosis of AMI, especially in those without regional wall motion 
abnormalities on echocardiography.(29) 
Although B type natriuretic peptides are promising across the entire 
spectrum of ACS, they are still in the early stages of widespread clinical 
use. There is a pressing need to address several assay-related issues, 
their application to different ethnic groups, and fi nally the cost-
effectiveness of these peptides before they are used on a large-scale 
clinical and epidemiological basis.
OTHER NOVEL MARKERS                                                  
A variety of other biomarkers have been evaluated in the context of 
ACS, but none are available for routine clinical use.
 Heart-type fatty acid binding protein (H-FABP) is a small cytosolic 
protein that behaves similarly to myoglobin in its kinetics and 
release.  It is released into the circulation in response to myocardial 
injury, and may provide added value to other cardiac biomarkers 
for the early diagnosis of AMI.(30)
 The albumin cobalt binding test, which measures the concentration 
of ischemia-modifi ed albumin (IMA), has been recently proposed 
for early detection of myocardial ischemia without infarction.(31) 
The main limitation of IMA at present is its low specifi city, since the 
test is positive in many conditions like cancer, infections, end-stage 
renal disease, liver disease and brain ischemia.  In addition, the need 
for adjustment for baseline albumin, and the frequent overlap 
between normal and abnormal values, renders this test diffi cult to 
interpret in many patients.
■
■
 The pregnancy-associated plasma protein-A (PAPP-A) is a zinc-
binding matrix metalloproteinase, which is expressed in eroded 
and ruptured atherosclerotic plaques.  The PAPP-A level has been 
recently acknowledged as a strong predictor of cardiovascular 
events in patients with ACS.(32)
 Increasing evidence suggests that soluble CD40 ligand plays an 
important part in disease progression and plaque destabilization.(33) 
Soluble CD40 ligand, which is expressed on platelets and released 
from them on activation, has been found to be a powerful 
biomarker of infl ammatory thrombotic activity in patients with 
ACS.(34)  Elevated levels of this biomarker can also identify patients 
with ACS who are at highest risk for cardiac events.  Therefore, 
soluble CD40 ligand not only contributes to the pathophysiology 
of ACS but also represents a reliable and powerful clinical marker 
for use in identifying patients with high-risk atherosclerotic lesions, 
coronary thrombosis, or both.(35,36)
 A promising new biomarker is growth differentiation factor 
15 (GDF-15), a member of the growth factor beta cytokine 
superfamily. GDF-15 is released from myocardial cells after ischemia 
and reperfusion injury and has recently been shown that circulating 
levels are a strong independent marker of 1-year mortality in 
patients with acute coronary syndrome.(37)
 Several other markers of infl ammation, which may show clinical 
promise, include lipoprotein-associated phospholipase A2, also 
known as platelet-activating factor acetylhydrolase,(38) tumor 
necrosis factor alpha,(39) myeloperoxidase,(40) interleukin-6 and 8, 
and the leucocyte adhesion molecules ICAM-1, VCAM-1, and 
P-selectin.(41)
CONCLUSIONS                                                                   
Although this overview has focused on the role of several cardiac 
biomarkers in ACS, it is important to recognize that the fundamental 
issue with all markers is that there is no gold standard for the diagnosis 
of cardiac ischemia. Everyone is interested in fi nding the next biomarker 
that will be more specifi c and possibly cheaper than the current 
biomarkers in the diagnosis and risk stratifi cation of ACS. Perhaps, 
ongoing efforts in plasma-based biomarker research should concentrate 
on the use of a multimarker approach to enhance our diagnosis, 
prognostic assessment and management of patients with suspected 
ACS, as compared with using individual markers alone. It is recommended 
that current practice involve the selective use of biomarkers in patients 
in whom a more complete assessment of risk is desired.  At present, 
routine biomarker measurement is not advocated until further data 
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